Clinuvel receives IND status
Thursday, 29 January, 2009
Melbourne’s Clinuvel has received investigational new drug (IND) status for its photoprotective drug afamelanotide from the US FDA.
The ruling will allow the company to begin clinical trials in the US. It received orphan drug designation from the FDA in July last year.
Afamelanotide is currently in Phase III trials for the treatment of erythropoietic protoporphyria (EPP) in Europe and Australia, amongst several other trials in UV-related skin disorders.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
